The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
Open accessAbstract
Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
Genetic Structure of Human Populations
Rosenberg, N. A., Pritchard, J. K., Weber, J. L., Cann, H. M., Kidd, K. K., Zhivotovsky, L. A., & Feldman, M. W. (2002) · Science · doi:10.1126/science.1078311 · Cited by 2,222
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
Pharmacogenomics Knowledge for Personalized Medicine
Whirl-Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F., Altman, R. B., & Klein, T. E. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.96 · Cited by 1,796
Self-citationGenetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,373
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
Relling, M. V., & Klein, T. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.279 · Cited by 1,164
Pharmacogenetics: From Bench to Byte— An Update of Guidelines
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.34 · Cited by 1,018
Self-citationCollet, J.-P., Hulot, J.-S., Pena, A., Villard, E., Esteve, J.-B., Silvain, J., Payot, L., Brugier, D., Cayla, G., Beygui, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61845-0 · Cited by 967
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
Self-citationThe CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Gaedigk, A., Simon, S., Pearce, R., Bradford, L., Kennedy, M., & Leeder, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100406 · Cited by 779
Self-citationDe Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., & Goldstein, J. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09788-3 · Cited by 752
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
Gillman, P. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707253 · Cited by 694
Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., Anderson, J. L., Kimmel, S. E., Lee, M. T. M., Pirmohamed, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.185 · Cited by 647
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., Morath, T., Schömig, A., von Beckerath, N., & Kastrati, A. (2010) · Circulation · doi:10.1161/circulationaha.109.885194 · Cited by 585
Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C.-H., Yee, S. W., Stein, C. M., Carrillo, M., Evans, W. E., & Klein, T. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.320 · Cited by 574
Clines, Clusters, and the Effect of Study Design on the Inference of Human Population Structure
Rosenberg, N. A., Mahajan, S., Ramachandran, S., Zhao, C., Pritchard, J. K., & Feldman, M. W. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010070 · Cited by 568
Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J.-S., Johnson, J. A., Roden, D. M., Klein, T. E., & Shuldiner, A. R. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.132 · Cited by 484
Self-citationRelationship between Plasma Level and Therapeutic Effect of Nortriptyline
Åsberg, M., Cronholm, B., Sjöqvist, F., & Tuck, D. (1971) · BMJ · doi:10.1136/bmj.3.5770.331 · Cited by 466
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Pulley, J. M., Denny, J. C., Peterson, J. F., Bernard, G. R., Vnencak-Jones, C. L., Ramirez, A. H., Delaney, J. T., Bowton, E., Brothers, K., Johnson, K., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.371 · Cited by 414
Roberts, J. D., Wells, G. A., Le May, M. R., Labinaz, M., Glover, C., Froeschl, M., Dick, A., Marquis, J.-F., O'Brien, E., Goncalves, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60161-5 · Cited by 391
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Shen, D. D., Callaghan, J. T., Kharasch, E. D., & Skaar, T. C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.287 · Cited by 371
Self-citationThe AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry
Gaertner, I., Baumann, P., Hiemke, C., Ulrich, S., Eckermann, G., Gerlach, M., Kuss, H., Laux, G., Müller-Oerlinghausen, B., Rao, M., et al. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-862645 · Cited by 343
Leckband, S. G., Kelsoe, J. R., Dunnenberger, H. M., George, A. L., Tran, E., Berger, R., Müller, D. J., Whirl-Carrillo, M., Caudle, K. E., & Pirmohamed, M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.103 · Cited by 335
Self-citationWilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., Krauss, R. M., Roden, D. M., Feng, Q., Cooper-DeHoff, R. M., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.57 · Cited by 332
Dahl, M. L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M., & Sjöqvist, F. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10669-1 · Cited by 313
Metabolism of Tricyclic Antidepressants
Rudorfer, M. V., & Potter, W. Z. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006949816036 · Cited by 296
Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population*
Kubota, T., Chiba, K., & Ishizaki, T. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90214-3 · Cited by 288
10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*
Dalén, P., Dahl, M.-L., Ruiz, M. L. B., Nordin, J., & Bertilsson, L. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90040-6 · Cited by 285
Pharmacogenetics: From Bench to Byte
Swen, J. J., Wilting, I., de Goede, A., Grandia, L., Mulder, H., Touw, D. J., de Boer, A., Conemans, J. M. H., Egberts, T. C. G., Klungel, O. H., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100507 · Cited by 269
Self-citationHammer, W., & Sjöqvist, F. (1967) · Life Sciences · doi:10.1016/0024-3205(67)90218-4 · Cited by 262
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
Li‐Wan‐Po, A., Girard, T., Farndon, P., Cooley, C., & Lithgow, J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03578.x · Cited by 262
Vega, F. M. D. L., Lazaruk, K. D., Rhodes, M. D., & Wenz, M. H. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2005.01.008 · Cited by 247
Rudberg, I., Mohebi, B., Hermann, M., Refsum, H., & Molden, E. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100291 · Cited by 232
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
Bertilsson, L., Dahl, M.-L., Sjöqvist, F., Åberg-Wistedt, A., Humble, M., Johansson, I., Lundqvist, E., & Ingelman-Sundberg, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)92546-6 · Cited by 223
Chang, M., Dahl, M.-L., Tybring, G., Gotharson, E., & Bertilsson, L. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00004 · Cited by 203
Ferguson, R. J., De Morais, S. M. F., Benhamou, S., Bouchardy, C., Blaisdell, J., Ibeanu, G., Wilkinson, G. R., Sarich, T. C., Wright, J. M., Dayer, P., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37213-1 · Cited by 199
Stingl, J. C., Brockmöller, J., & Viviani, R. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.42 · Cited by 198
Self-citationThe Pharmacologic Treatment of Depression
Oates, J. A., Wood, A. J. J., Potter, W. Z., Rudorfer, M. V., & Manji, H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108293250907 · Cited by 195
Dahl, M.-L., Johansson, I., Palmertz, M. P., Ingelman-Sundberg, M., & Sjöqvist, F. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.2 · Cited by 186
The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping.
Tobler, A. R., Short, S., Andersen, M. R., Paner, T. M., Briggs, J. C., Lambert, S. M., Wu, P. P., Wang, Y., Spoonde, A. Y., Koehler, R. T., et al. (2005) · PubMed · Cited by 183
Steimer, W., Zöpf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., Messner, B., Kissling, W., & Leucht, S. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.041327 · Cited by 181
Xiao, Z.-S., Goldstein, J. A., Xie, H.-G., Blaisdell, J., Wang, W., Jiang, C.-H., Yan, F.-X., He, N., Huang, S.-L., Xu, Z.-H., et al. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36606-6 · Cited by 174
The Emerging Role of Cytochrome P450 3A in Psychopharmacology
Ketter, T. A., Flockhart, D. A., Post, R. M., Denicoff, K., Pazzaglia, P. J., Marangell, L. B., George, M. S., & Callahan, A. M. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199512000-00002 · Cited by 172
Grasm�der, K., Verwohlt, P., Rietschel, M., Dragicevic, A., M�ller, M., Hiemke, C., Freymann, N., Zobel, A., Maier, W., & Rao, M. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0766-8 · Cited by 161
�gren, H., Bertilsson, L., Kawanishi, C., & Lundgren, S. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0701-4 · Cited by 159
Chen, S., Chou, W.-H., Blouin, R. A., Mao, Z. L., Humphries, L. L., Meek, Q. C., Neill, J. R., Martin, W. L., Hays, L. R., & Wedlund, P. J. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90148-4 · Cited by 149
The Treatment of Neuropathic Pain: Antidepressants and Opioids
Watson, P. C. N. (2000) · Clinical Journal of Pain · doi:10.1097/00002508-200006001-00009 · Cited by 147
Baldwin, R. M., Ohlsson, S., Pedersen, R. S., Mwinyi, J., Ingelman‐Sundberg, M., Eliasson, E., & Bertilsson, L. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03104.x · Cited by 146
Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes
Stingl, J., & Seeringer, A. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.09.019 · Cited by 143
Self-citationPlasma levels of chlorimipramine and its demethyl metabolite during treatment of depression
Träskman, L., Åsberg, M., Bertiisson, L., Cronholm, B., Mellström, B., Neckers, L. Μ., Sjöqvist, F., Thorén, P., & Tybring, G. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1979265600 · Cited by 142
Skjelbo, E., Brøsen, K., Hallas, J., et al. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.4 · Cited by 141
Steimer, W., Zöpf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., Meßner, B., Kissling, W., & Leucht, S. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.030825 · Cited by 141
Zackrisson, A.-L., Lindblom, B., & Ahlner, J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.216 · Cited by 132
Ibeanu, G. C., Goldstein, J. A., Meyer, U., Benhamou, S., Bouchardy, C., Dayer, P., Ghanayem, B. I., & Blaisdell, J. A. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37748-1 · Cited by 127
Comparison of Two CYP2D6 Genotyping Methods and Assessment of Genotype-Phenotype Relationships
Chou, W.-H., Yan, F., Robbins‐Weilert, D., et al. (2003) · Clinical Chemistry · doi:10.1373/49.4.542 · Cited by 121
Influence of the CYP2D6 * 4 polymorphism on dose, switching and discontinuation of antidepressants
Bijl, M. J., Visser, L. E., Albert Hofman, D., Vulto, A. G., van Gelder, T., Stricker, B. H. C., & van Schaik, R. H. N. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03052.x · Cited by 117
Brøsen, K., Zeugin, T., & Meyer, U. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.77 · Cited by 114
Johnson, J. A., Burkley, B., Langaee, T. Y., Clare-Salzler, M. J., Klein, T. E., & Altman, R. B. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.125 · Cited by 112
Plasma Level Monitoring of Tricyclic Antidepressant Therapy
Gram, L. F. (1977) · Clinical Pharmacokinetics · doi:10.2165/00003088-197702040-00001 · Cited by 111
Ibeanu, G. C., Blaisdell, J. A., Ferguson, R. J., Ghanayem, B. I., Brøsen, K., Benhamou, S., Bouchardy, C., Wilkinson, G. R., Dayer, P., & Goldstein, J. A. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34944-4 · Cited by 110
Pratt, V. M., Zehnbauer, B. A., Amos, J. A., Baak, R., Babić, N., Bettinotti, M. P., Buller, A. M., Butz, K., Campbell, M., Civalier, C., et al. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.100090 · Cited by 109
Comparative Tolerability Profiles of the Newer versus Older Antidepressants
Rudorfer, M. V., Manji, H. K., & Potter, W. Z. (1994) · Drug Safety · doi:10.2165/00002018-199410010-00003 · Cited by 106
Spina, E., Gitto, C., Avenoso, A., Campo, G. M., Caputi, A. P., & Perucca, E. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050220 · Cited by 103
Br�sen, K., Klysner, R., Gram, L. F., Otton, S. V., Bech, P., & Bertilsson, L. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00608215 · Cited by 102
The Star-Allele Nomenclature: Retooling for Translational Genomics
Robarge, J., Li, L., Desta, Z., Nguyen, A., & Flockhart, D. A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100284 · Cited by 101
Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype
Brøsen, K., Otton, S. V., & Gram, L. F. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.221 · Cited by 100
Ibeanu, G. C., Blaisdell, J. A., Ghanayem, B. I., et al. (1998) · Pharmacogenetics · doi:10.1097/00008571-199804000-00006 · Cited by 98
Sequence-based CYP2D6 Genotyping in the Korean Population
Lee, S., Sohn, K.-M., Ryu, J. Y., Yoon, Y. R., Shin, J., & Kim, J.-W. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000211823.80854.db · Cited by 97
The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers
Tamminga, W. J., Wemer, J., Oosterhuis, B., de Zeeuw, R., de Leij, L., & Jonkman, J. H. G. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100359 · Cited by 95
Desipramine Plasma Concentration and Antidepressant Response
Nelson, J. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290120049010 · Cited by 95
Hicks, J. K., Crews, K. R., Hoffman, J. M., Kornegay, N. M., Wilkinson, M. R., Lorier, R., Stoddard, A., Yang, W., Smith, C. J., Fernandez, C. A., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.140 · Cited by 95
Self-citationToxicity of tricyclic antidepressants--kinetics, mechanism, intervention: a review.
Preskorn, S. H., & Ha, I. (1982) · PubMed · Cited by 95
Gurbel, P. A., Tantry, U. S., Shuldiner, A. R., & Kereiakes, D. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.008 · Cited by 91
Nielsen, K. K., Brøsen, K., Hansen, M. G. J., & Gram, L. F. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.65 · Cited by 91
de León, J., Susce, M. T., Johnson, M., Hardin, M., Maw, L., Shao, A., Allen, A. C. P., Chiafari, F. A., Hillman, G. R., & Nikoloff, D. M. (2009) · CNS Spectrums · doi:10.1017/s1092852900020022 · Cited by 88
Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes
Breyer-Pfaff, U., Pfandl, B., Nill, K., et al. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.155 · Cited by 88
First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype
Brøsen, K., & Gram, L. F. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.50 · Cited by 86
Harmsze, A. M., van Werkum, J. W., Hackeng, C. M., Ruven, H. J. T., Kelder, J. C., Bouman, H. J., Breet, N. J., ten Berg, J. M., Klungel, O. H., de Boer, A., et al. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834ff6e3 · Cited by 85
Management of Cancer Pain: Basic Principles and Neuropathic Cancer Pain
Laird, B. J. A., Colvin, L., & Fallon, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.022 · Cited by 84
Yue, Q., Zhong, Z., Tybring, G., et al. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90069-8 · Cited by 82
Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers
Mellström, B., Säwe, J., Bertilsson, L., & Sjöqvist, F. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.56 · Cited by 81
Dahl, M. L., Bertilsson, L., & Nordin, C. (1996) · Psychopharmacology · doi:10.1007/bf02246640 · Cited by 75
Metabolic Ratios of Psychotropics as Indication of Cytochrome P450 2D6/2C19 Genotype
van der Weide, J., van Baalen-Benedek, E. H., & Kootstra‐Ros, J. E. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000162868.84596.c3 · Cited by 75
Achieving remission and managing relapse in depression.
Thase, M. E. (2003) · PubMed · Cited by 70
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
Rosenborg, S., Mwinyi, J., Andersson, M., Baldwin, R. M., Pedersen, R. S., Sim, S. C., Bertilsson, L., Ingelman‐Sundberg, M., & Eliasson, E. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0529-z · Cited by 68
de Vos, A., van der Weide, J., & Loovers, H. M. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.39 · Cited by 66
A Fatal Doxepin Poisoning Associated With a Defective CYP2D6 Genotype
Koski, A., Ojanperä, I. A., Sistonen, J., Vuori, E., & Sajantila, A. (2007) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0b013e3180326701 · Cited by 65
Association between CYP2C19 polymorphism and depressive symptoms
Sim, S. C., Nordin, L., Andersson, T., Virding, S., Olsson, M., Pedersen, N. L., & Ingelman‐Sundberg, M. (2010) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31081 · Cited by 64
Single-Dose Kinetics Predict Steady-State Concentrations of Imipramine and Desipramine
Potter, W. Z., Zavadil, A. P., Kopin, I. J., & Goodwin, F. K. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780160084010 · Cited by 63
Shimoda, K., Someya, T., Yokono, A., Morita, S., Hirokane, G., Takahashi, S., & Okawa, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00007 · Cited by 61
Baumann, P., Jonzier-Perey, M., Koeb, L., et al. (1986) · International Clinical Psychopharmacology · doi:10.1097/00004850-198604000-00002 · Cited by 60
Morita, S., Shimoda, K., Someya, T., Yoshimura, Y., Kamijima, K., & Kato, N. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00005 · Cited by 60
Murphy, G. M., Pollock, B. G., Kirshner, M. A., Pascoe, N., Cheuk, W., Mulsant, B. H., & Reynolds, C. F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00289-5 · Cited by 57
Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics
Kirchheiner, J., Müller, G., Meineke, I., Wernecke, K., Roots, I., & Brockmöller, J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000088909.24613.92 · Cited by 57
Ulrich, S., & L??uter, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00004 · Cited by 54
Schenk, P. W., van Fessem, M., Rij, S. V.-V., Mathôt, R. A. A., van Gelder, T., Vulto, A. G., van Vliet, M., Lindemans, J. W., Bruijn, J. A., & van Schaik, R. H. N. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002057 · Cited by 53
Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods
Fernandez, C. A., Smith, C. J., Yang, W., Lorier, R., Crews, K. R., Kornegay, N., Hicks, J. K., Stewart, C. F., Kawedia, J. D., Ramsey, L. B., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.95 · Cited by 49
Self-citationPharmacogenetic Screening of the Gene Deletion and Duplications of CYP2D6
Meijerman, I., Sanderson, L. M., Smits, P. H. M., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530600952206 · Cited by 49
Eap, C. B., Bender, S., Gastpar, M., et al. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200004000-00012 · Cited by 47
The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects
Jiang, Z., Shu, Y., Chen, X., Huang, S., Zhu, R., Wang, W., He, N., & Zhou, H. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0445-6 · Cited by 46
Schenk, P. W., van Vliet, M., Mathôt, R. A. A., van Gelder, T., Vulto, A. G., van Fessem, M., Rij, S. V.-V., Lindemans, J. W., Bruijn, J. A., & van Schaik, R. H. N. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.50 · Cited by 46
Morinobu, S., Tanaka, T., Kawakatsu, S., Totsuka, S., Koyama, E., CHIBA, K., Ishizaki, T., & Kubota, T. (1997) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1997.tb02593.x · Cited by 45
Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy
Lyon, E., Gastier, J. M., Palomaki, G. E., Pratt, V. M., Reynolds, K. K., Sábato, M. F., Scott, S. A., & Vitazka, P. (2012) · Genetics in Medicine · doi:10.1038/gim.2012.108 · Cited by 45
Therapeutic Monitoring of Psychotropic Drugs
Baumann, P., Hiemke, C., Ulrich, S., Gaertner, I., Rao, M. L., Eckermann, G., Gerlach, M., Kuss, H., Laux, G., Müller-Oerlinghausen, B., et al. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00014 · Cited by 43
Cytochrome P450 Monooxygenases and Interactions of Psychotropic Drugs: A Five-Year Update
Shen, W. W. (1995) · The International Journal of Psychiatry in Medicine · doi:10.2190/29np-2xpn-x0me-mqwu · Cited by 43
Yokono, A., Morita, S., Someya, T., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200112000-00002 · Cited by 42
Koyama, E., Tanaka, T., Chiba, K., Kawakatsu, S., Morinobu, S., Totsuka, S., & Ishizaki, T. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199608000-00003 · Cited by 42
Koyama, E., Sohn, D., Shin, S. G., et al. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23847-2 · Cited by 41
SCHNEIDER, L. S., Cooper, T. B., Severson, J. A., Zemplenyi, T., & Sloane, R. B. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198812000-00004 · Cited by 39
High Blood Concentrations of Imipramine or Clomipramine and Therapeutic Failure
Balant-Gorgia, A. E., Balant, L. P., & Garrone, G. (1989) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198907000-00008 · Cited by 39
Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics
Furman, K. D., Grimm, D. R., Mueller, T., Holley-Shanks, R. R., Bertz, R., Williams, L. A., Spear, B. B., & Katz, D. A. (2004) · Pharmacogenetics · doi:10.1097/00008571-200405000-00002 · Cited by 38
Bluhm, R. E., Wilkinson, G. R., Shelton, R. C., & Branch, R. A. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.13 · Cited by 38
Müller, D. J., Brandl, E. J., Hwang, R., Tiwari, A. K., Sturgess, J. E., Zai, C. C. H., Lieberman, J. A., Kennedy, J. L., & Richter, M. A. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2011.0327 · Cited by 35
Self-citationQuantitative Pharmacogenetics of Nortriptyline
Kvist, E. E., Al‐Shurbaji, A., Dahl, M., Nordin, C., n, G. A., & hle, L. S. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140110-00005 · Cited by 33
Kirchheiner, J., Sasse, J., Meineke, I., Roots, I., & ller, J. R. B. (2003) · Pharmacogenetics · doi:10.1097/00008571-200312000-00003 · Cited by 30
Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4*
Madsen, H., Rasmussen, B. B., & Brøsen, K. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90164-8 · Cited by 28
Gene Copy Number Variations: It is Important to Determine which Allele is Affected
Ramamoorthy, A., & Skaar, T. C. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.5 · Cited by 28
Self-citationPronounced Differences in the Disposition of Clomipramine Between Japanese and Swedish Patients
Shimoda, K., Jerling, M., Böttiger, Y., et al. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00002 · Cited by 28
Baumann, P., Broly, F., Kosel, M., & Eap, C. B. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979303 · Cited by 27
Halling, J., Weihe, P., & Brøsen, K. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02969.x · Cited by 25
Skjelbo, E., Gram, L. F., & Brøsen, K. (1993) · PubMed · Cited by 24
Desipramine and 2-Hydroxydesipramine Plasma Levels in Endogenous Depressed Patients
Amsterdam, J. D. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790270051005 · Cited by 23
Dalen, P. A. V., Dahl, M.-L., Hk, R., et al. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01804.x · Cited by 15
Shimoda, K., YASUDA, S., Morita, S., Shibasaki, M., Someya, T., Bertilsson, L., & Takahashi, S. (1997) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1997.tb02364.x · Cited by 15
Tacke, U., Leinonen, E. V. J., Lillsunde, P. M., Seppälä, T. T., Arvela, P. I., Pelkonen, O., & Ylitalo, P. (1992) · PubMed · Cited by 15
2-Hydroxydesipramine and Desipramine Plasma Levels and
Stern, S. L., Ribner, H. S., Cooper, T. B., Nelson, L. D., JOHNSON, M. H., & Suckow, R. F. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199104000-00004 · Cited by 13
Lee, S., Ki, C., Hong, K. S., et al. (2004) · Journal of Korean Medical Science · doi:10.3346/jkms.2004.19.5.750 · Cited by 12
Imipramine metabolism in relation to the sparteine oxidation polymorphism - a family study
Madsen, H., Hansen, T. S., & Brøsen, K. (1996) · Pharmacogenetics · doi:10.1097/00008571-199612000-00004 · Cited by 9
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Self-citationMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel, U., Howard, S. C., Hunkler, R. J., Klein, T. E., Evans, W. E., & Relling, M. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124835 · Cited by 511
Prediction of CYP2D6 phenotype from genotype across world populations
Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T., & Leeder, J. S. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.80 · Cited by 506
Self-citationCaudle, K., Klein, T., Hoffman, J., Muller, D., Whirl-Carrillo, M., Gong, L., McDonagh, E., Sangkuhl, K., Thorn, C., Schwab, M., et al. (2014) · Current Drug Metabolism · doi:10.2174/1389200215666140130124910 · Cited by 446
Self-citation
Metadata
- Authors
- Hicks, J. K., Swen, J. J., Thorn, C. F., Sangkuhl, K., Kharasch, E. D., Ellingrod, V. L., Skaar, T. C., Müller, D. J., Gaedigk, A., & Stingl, J. C.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2013-01-16
- Volume
- 93
- Issue
- 5
- Pages
- 402-408
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2021635654
- Cited by
- 453
- References
- 134
- FWCI
- 61.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.